Market Scope uses a multi-source methodology when preparing our annual and quarterly reports. We incorporate surgeon surveys, our extensive database of physicians and surgery centers, disease models, clinical studies, financial reports, and more. Our wide-ranging knowledge of products and technology and our comprehensive network of industry contacts also contribute to our coverage on the ophthalmic industry.
Market Scope’s “2022 European Five Ophthalmic Market Report” analyzes the ophthalmic market in Western Europe’s five largest economies, discussing important trends and key factors for future success in 11 ophthalmic submarkets. The report includes forecasts of disease prevalence, numbers of treatments, and technologies used in treatments. It profiles ophthalmic companies in the five markets, provides analysis of current markets, and offers five-year forecasts of market performance.
The second-edition “2021 Ophthalmic Landscape Report” offers a high-level analysis of the 2021 global ophthalmic market by region and subspecialty and forecasts market performance over the next five years. It discusses important trends and key factors for future success.
The “2022 Ophthalmic Laser Market Report” offers a comprehensive analysis of the global market for ophthalmic lasers, as well as a discussion of important trends and key factors shaping future success. The report covers photocoagulation, photodisruption, and SLT lasers with market data for 2021 and forecasts through 2027. Product demand is forecast in units and dollars, and market share is analyzed by product category. Seventeen market competitors are profiled, with discussion of their products, strategic market position, background, and outlook.
This report is designed for ophthalmic industry manufacturers, market analysts, providers, and investors who are interested in the ophthalmic lasers business and related products. In-depth topics include laser treatment estimates, ophthalmic surgeons using lasers, and manufacturers of ophthalmic lasers (excluding femtosecond and excimer lasers).
Our coverage of the US glaucoma surgery market includes a quarterly surveying process that targets and collects data from glaucoma surgeons. The resulting data are analyzed and presented in our US Glaucoma Surgery Quarterly Updates. These updates are designed to improve your decision-making process with an assessment of current market conditions and the identification of significant market trends -- including a variety of vital practice of medicine issues, doctors’ evaluations of pharmaceuticals and surgical equipment, product use and market share, product adoption plans, and the identification of significant trends in the marketplace for the treatment of glaucoma.
Each update includes full-year forecasts, comparisons with prior years, and trend analysis.
The “2022 Glaucoma Surgical Device Market Report” offers a comprehensive analysis of the current global market for glaucoma devices, as well as a discussion of important trends and key factors shaping future success. The report covers prevalence for glaucoma worldwide and discusses the ophthalmologists who treat glaucoma. It also examines the role of surgical intervention, the market dynamics for currently commercialized products, and the pipeline of investigational devices that may offer improved outcomes. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Twenty-four market competitors are profiled, with discussion of their products, strategic market position, background, and outlook.
The “2022 China Ophthalmic Market Report” is the leading industry source for accurate and relevant information on all aspects of China’s ophthalmic market. This report provides a comprehensive overview of the Chinese population and economic conditions. It also covers disease prevalence and therapeutic approaches, including commercialized and pipeline products. The report analyzes unit demand and revenue, and it forecasts future performance over the next five years. It also includes market share data and discusses key strategic issues. Additionally, 31 market competitors are profiled, with discussion of their products, strategic market position, background, and outlook.
The “2022 United States Glaucoma Atlas” provides a geographic analysis of the glaucoma population and treatment opportunity in 85 US metropolitan areas. Market Scope’s proprietary MedOp Index Analysis™ analyzes market potential and provides a benchmark against other atlas metros. The atlas offers strategic insights into the top potential markets in the US, which companies often use throughout the development and commercialization processes to identify ideal clinical trial locations, develop launch strategies, define sales territories, allocate resources, and optimize sales and marketing initiatives.
The “2022 India Ophthalmic Market Report” analyzes the current landscape of the Indian ophthalmic market, discussing important trends and key factors for future success, and includes forecasts of disease prevalence, numbers of treatments, and technologies used in treatments. The report analyzes the Indian markets for diagnostic equipment, lasers, cataract, refractive, cornea, glaucoma, retina, dry eye, surgical instruments, and single-use surgical devices. Thirty market competitors are profiled, with discussion of their products, strategic market positions, background, and outlook.
Market Scope’s 2021 Glaucoma Disease Model offers extensive country-level prevalence data and five-year forecasts for glaucoma by type and by age group for all countries with a population over a million.
This proprietary model takes into consideration the latest clinical research and demographic projections on a global scale and can be customized by geography and disease category to meet clients’ diverse needs. Disease models can be used to evaluate target markets for clinical-stage and commercial-stage products and gain insights into the volume and demographics of diseased populations.
The “2022 Glaucoma Pharmaceuticals Market Report” analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2027 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 29 glaucoma pharmaceutical companies are profiled, discussing their products, strategic market position, background, and outlook.
In addition to our standard comprehensive reports, we also leverage our expert knowledge of the ophthalmic industry to design custom research that enhances strategy and operations for our clients. Our unique experience makes us a trusted partner in defining problems and executing solutions.
Common project types include custom data analysis, surveying and/or interviewing of ophthalmologists, focus groups, territory analyses, and other primary research initiatives -- but each project is custom designed to meet each specific clients' needs.
Please contact us for an individualized project consultation.
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.